TY  - JOUR
AU  - Ritzmann, Timothy A
AU  - Chapman, Rebecca J
AU  - Kilday, John-Paul
AU  - Thorp, Nicola
AU  - Modena, Piergiorgio
AU  - Dineen, Robert A
AU  - Macarthur, Donald
AU  - Mallucci, Conor
AU  - Jaspan, Timothy
AU  - Pajtler, Kristian
AU  - Giagnacovo, Marzia
AU  - Jacques, Thomas S
AU  - Paine, Simon M L
AU  - Ellison, David W
AU  - Bouffet, Eric
AU  - Grundy, Richard G
TI  - SIOP Ependymoma I: Final results, long term follow-up and molecular analysis of the trial cohort: A BIOMECA Consortium Study.
JO  - Neuro-Oncology
VL  - 24
IS  - 6
SN  - 1522-8517
CY  - Oxford
PB  - Oxford Univ. Press
M1  - DKFZ-2022-00102
SP  - 936-948
PY  - 2022
N1  -  2022 Jun 1;24(6):936-948
AB  - SIOP Ependymoma I was a non-randomised trial assessing event free and overall survival (EFS/OS) of non-metastatic intracranial ependymoma in children aged 3 to 21 years treated with a staged management strategy. A further aim was to assess the response rate (RR) of subtotally resected (STR) ependymoma to vincristine, etoposide and cyclophosphamide (VEC). We report final results with 12-year follow-up and post hoc analyses of recently described biomarkers.74 participants were eligible. Children with gross total resection (GTR) received radiotherapy, whilst those with STR received VEC before radiotherapy. DNA methylation, 1q, hTERT, ReLA, Tenascin-C, H3K27me3 and pAKT status were evaluated.Five- and ten-year EFS was 49.5
KW  - Chemotherapy (Other)
KW  - Ependymoma (Other)
KW  - Radiotherapy (Other)
KW  - Recurrence (Other)
KW  - Resection (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:35018471
DO  - DOI:10.1093/neuonc/noac012
UR  - https://inrepo02.dkfz.de/record/178484
ER  -